Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.

BACKGROUND--Pulmonary disease caused by Mycobacterium kansasii is reported in approximately 50 new patients in Britain annually. Rifampicin and ethambutol are effective in vitro but the optimal duration of treatment, and whether isoniazid should also be given, are uncertain. The British Thoracic Society has conducted a prospective, multicentre study of the treatment of this condition with rifampicin and ethambutol given for nine months. METHODS--One hundred and seventy three patients with two or more positive cultures and radiological evidence of disease were recruited via the Mycobacterium Reference Unit (PHLS) in Cardiff from 113 physicians in England, Scotland, and Wales. Rifampicin and ethambutol were given for nine months, other antituberculosis drugs being discontinued once the culture was identified as M kansasii. Patients were reviewed, sputum cultured, and chest radiographs performed before, during, and at regular intervals for 51 months after chemotherapy. RESULTS--The mean (SD) age was 55.5 (11.7) years, 73% were men, and 50% had other lung problems. Cavitation was seen in 88%, bilateral shadowing in 48%, and three or more lung zones were affected in 46%. All cultures were sensitive to rifampicin and ethambutol but resistant to isoniazid and pyrazinamide. One patient who took chemotherapy irregularly still had positive cultures at seven and eight months. Fifteen patients developed positive cultures after the end of chemotherapy; factors which might account for the relapse were identified in eight. Reinfection rather than relapse was suspected in three of the 15. Radiographic improvement stabilised within three years in 80%. CONCLUSIONS--M kansasii pulmonary infection responds well to nine months of treatment with rifampicin and ethambutol but patients who contract this disease have a high mortality rate from other causes. Isoniazid does not appear to be a necessary part of the regimen.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Infection with Mycobacterium kansasii.

P D Davies
Thorax 1994 49: 435-436. [PDF]

This article has been cited by other articles:

• Santin, M., Dorca, J., Alcaide, F., Gonzalez, L., Casas, S., Lopez, M., Guerra, M. R. (2009). Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J 33: 148-152 [Abstract] [Full Text]  
• Glassroth, J. (2008). Pulmonary Disease Due to Nontuberculous Mycobacteria. Chest 133: 243-251 [Abstract] [Full Text]  
• Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., Iseman, M., Olivier, K., Ruoss, S., von Reyn, C. F., Wallace, R. J. Jr., Winthrop, K., on behalf of the ATS Mycobacterial Diseases Subcom, (2007). An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am. J. Respir. Crit. Care Med. 175: 367-416 [Full Text]  
• Dailloux, M., Abalain, M. L., Laurain, C., Lebrun, L., Loos-Ayav, C., Lozniewski, A., Maugein, J., the French Mycobacteria Study Group, (2006). Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J 28: 1211-1215 [Abstract] [Full Text]  
• Field, S. K., Cowie, R. L. (2006). Lung Disease Due to the More Common Nontuberculous Mycobacteria. Chest 129: 1653-1672 [Abstract] [Full Text]  
• Shitrit, D., Baum, G. L., Priess, R., Lavy, A., Shitrit, A. B.-G., Raz, M., Shlomi, D., Daniele, B., Kramer, M. R. (2006). Pulmonary Mycobacterium kansasii Infection in Israel, 1999-2004: Clinical Features, Drug Susceptibility, and Outcome. Chest 129: 771-776 [Abstract] [Full Text]  
• Benton, N., Musaad, S., Vaughan, R., McLean, L. (2004). Recurrent multifocal Mycobacterium kansasii infection in an immunosuppressed patient with myelodysplasia and relapsing polychondritis. Rheumatology (Oxford) 43: 1453-1454 [Full Text]  
• Henry, M.T., Inamdar, L., O'Riordain, D., Schweiger, M., Watson, J.P. (2004). Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J 23: 741-746 [Abstract] [Full Text]  
• Cynamon, M. H., Elliott, S. A., DeStefano, M. S., Yeo, A. E. T. (2003). Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection. J Antimicrob Chemother 52: 306-307 [Abstract] [Full Text]  
• The Research Committee of the British Thoracic Soc, (2003). Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur Respir J 21: 478-482 [Abstract] [Full Text]  
• ORMEROD, P (2001). A step forward in the evidence-based treatment of opportunist mycobacteria. Thorax 56: 163-163 [Full Text]  
• White, V L C, Al-Shahi, R, Gamble, E, Brown, P, Davison, A G (2001). Transverse myelopathy and radiculomyelopathy associated with pulmonary atypical Mycobacterium infections. Thorax 56: 158-160 [Abstract] [Full Text]  
• Subcommittee of the Joint Tuberculosis Committee o, (2000). Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 55: 210-218 [Full Text]  
• CORBETT, E. L., BLUMBERG, L., CHURCHYARD, G. J., MOLOI, N., MALLORY, K., CLAYTON, T., WILLIAMS, B. G., CHAISSON, R. E., HAYES, R. J., DE COCK, K. M. (1999). Nontuberculous Mycobacteria . Defining Disease in a Prospective Cohort of South African Miners. Am. J. Respir. Crit. Care Med. 160: 15-21 [Abstract] [Full Text]  
• (1997). Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria. Am. J. Respir. Crit. Care Med. 156: 1-25 [Full Text]